ABBV Ticker Curator

AbbVie's 30% 2025 stock surge finds support in its latest free cash flow of $19.9 billion, with analyst forecasts predicting rises over the next five years.

Strategic expansion in Durham, NC: $1.4B on 185-acre campus creates 734 jobs (engineers, scientists) at $118k avg wage, plus 2,000 construction...

Strategic US expansion ramps up with a 185-acre Durham hub, AbbVie's biggest single-campus capex at $1.4 billion.

• Creates 730+ jobs; produces...

• $1.4 billion investment for 185-acre pharmaceutical manufacturing campus in Durham, NC
• Announced April 22, 2026, via PRNewswire from North Chicago
• Confirmed by TipRanks as key ABBV (NYSE: ABBV) development

AbbVie's novel legal argument—hinging on a single word—could upend the 340B Drug Pricing Program. The drugmaker sued HRSA this month amid ongoing litigation. Watch for ripples in ABBV's pricing battles.

AbbVie (NYSE: ABBV) increased its quarterly cash dividend by 12.3%, from $0.57 to $0.64 per share. Payable February 15, this move highlights strong shareholder value commitment.

• Consensus: EPS $2.69 (+9.4% YoY), revenue $14.78B (+10.8% YoY)
• Red flag: EPS estimates down 0.7% in last 30 days; Earnings ESP -2.65% with Zacks...

AbbVie (NYSE:ABBV) has completed its acquisition of clinical-stage biotech Capstan Therapeutics for up to $2.1B. The deal was first announced in late June.

• Bernstein caution: Maintains Hold on ABBV with $225 PT
• Company outlook: FY26 EPS guided at $14.37-14.57, Q1 at $2.97-3.01
• Timing: Q1 earnings projected for Wednesday

Analyst restraint meets firm guidance—watch for alignment post-report.

Market Highlights

• 🔥 Stock Jump: Shares of AbbVie jumped 4.2% higher as of 11:37 a.m. ET on Thursday.
• 🔥 Trading Volume Surge: AbbVie's stock...

• Price surge: ABBV shares up 4.2% as of 11:37 a.m. ET Thursday after settlement reveal.
• Record liquidity: Tops U.S. equity turnover with 1.59B...

• Canaccord Genuity initiates AbbVie (ABBV) coverage at Buy with $262 price target
• Above consensus overweight average rating and $255.37 mean PT from FactSet analysts
• Fresh bullish signal amid analyst optimism.

ABBV is aligning its pipeline for multiple late-stage launches, including Rinvoq label expansions, Parkinson’s treatments, and oncology assets nearing FDA decisions. Key catalysts ahead.

Canaccord Genuity has initiated coverage on ABBV with a $262 price target, well above the current price of $205.14. Yet GF Value™ flags it as 2.3% overvalued versus $200.51 intrinsic value.

Revolution Medicines shares soared after reports of advanced talks for AbbVie to acquire the cancer-drug maker, fueling takeover speculation and potential oncology pipeline boost for ABBV.

Oncology angle on 2026 growth:

• Modest Emrelis start: Approved May 2025, sales contributed positively to top line despite being modest.
• Unpriced...

AbbVie (ABBV) announced the expansion of its partnership with BioLabs by becoming the founding sponsor of the new BioLabs University of Toronto.

Analyst Coverage

• 🔥 Canaccord Initiates Buy: Canaccord initiated coverage of AbbVie with a Buy rating and $262 price target, stating it should...

Canaccord initiated coverage of AbbVie (ABBV) with a Buy rating and $262 price target, believing it should be a core holding.

AbbVie (NYSE:ABBV) has agreed to a major Humira discount through the new government-run TrumpRx platform in the U.S., while weighing this against neurology pipeline commitments alongside partner Roche.